": 479 Narcissism can thus be seen as a symptom of fundamentally low self-esteem, that is, lack of love towards oneself, but often accompanied by "an immense increase in self-esteem" based on "the defense mechanism of denial by overcompensation." "Idealized love of self...rejected the part of him" that he denigrates – "this destructive little child" within. Instead, the narcissist emphasizes their virtues in the presence of others, just to try to convince themself that they are a valuable person and to try to stop feeling ashamed for their faults;  such "people with unrealistically inflated self-views, which may be especially unstable and highly vulnerable to negative information,...tend to have poor social skills. ": 126

See also
References
Further reading
Baumeister, Roy F. (2001). "Violent Pride: Do people turn violent because of self-hate or self-love?," in Scientific American, 284, No. 4, pp. 96–101; April 2001. Branden, N. (1969). The Psychology of Self-Esteem. New York: Bantam. Branden, N. (2001). The psychology of self-esteem: a revolutionary approach to self-understanding that launched a new era in modern psychology. San Francisco: Jossey-Bass, 2001. ISBN 0787945269
Burke, C. (2008) "Self-esteem: Why? ; Why not?," New York: 2008
Crocker J.; Park L. E. (2004). "The costly pursuit of self-esteem". Psychological Bulletin. 130 (3): 392–414. doi:10.1037/0033-2909.130.3.392. PMID 15122925. Franklin, Richard L. (1994). "Overcoming The Myth of Self-Worth: Reason and Fallacy in What You Say to Yourself." ISBN 0963938703
Hill, S.E. & Buss, D.M. (2006). "The Evolution of Self-Esteem." In Michael Kernis, (Ed. ), Self Esteem: Issues and Answers: A Sourcebook of Current Perspectives.. Psychology Press:New York. 328–33. Full text
Lerner, Barbara (1985).
During VL, interferon gamma is not produced by peripheral blood mononuclear cells (PBMC). After treatment of VL, PBMCs start producing interferon gamma, which coincides with the appearance of PKDL lesions due to interferon-gamma-producing cells causing skin inflammation as a reaction to persisting parasites in the skin. Diagnosis
PKDL is difficult to diagnose.Diagnosis is mainly clinical, but parasites can be seen by microscopy in smears with limited sensitivity. PCR and monoclonal antibodies may detect parasites in more than 80% of cases. Serological tests and the leishmanin skin test are of limited value. Treatment
Treatment is always needed in Indian PKDL; in Sudan, most cases are self-limited but severe and chronic cases are treated. Sodium stibogluconate is given at 20 mg/kg for 2 months in Sudan and for 4 months in India. Liposomal amphotericine B seems effective. Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention.Miltefosine is the only available oral medication available for VL and PKDL. While the drug works for short-term treatment of VL, PKDL would require a longer treatment of more than 28 days with this drug. Miltefosine is not recommended for use as a monotherapy to treat PKDL. Society and culture
People with PKDL are a reservoir of leishmaniasis. To eliminate leishmaniasis from a population, people with PKDL must get treatment.The government of India has an kala-azar elimination program ongoing which entered a consolidation phase in 2017. See also
List of cutaneous conditions


== References ==